| __timestamp | Alpine Immune Sciences, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 7461000 |
| Thursday, January 1, 2015 | 6844000 | 11960000 |
| Friday, January 1, 2016 | 8586000 | 13108000 |
| Sunday, January 1, 2017 | 6079000 | 17501000 |
| Monday, January 1, 2018 | 8362000 | 22472000 |
| Tuesday, January 1, 2019 | 9467000 | 24286000 |
| Wednesday, January 1, 2020 | 10899000 | 29689000 |
| Friday, January 1, 2021 | 14560000 | 38837000 |
| Saturday, January 1, 2022 | 17968000 | 47489000 |
| Sunday, January 1, 2023 | 22222000 | 53379000 |
Data in motion
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, Alpine Immune Sciences, Inc. and Xencor, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Alpine Immune Sciences, Inc. started with a modest $2.3 million in 2014, growing nearly tenfold to $22.2 million by 2023. This represents a significant increase, highlighting their expanding operational scale.
Conversely, Xencor, Inc. began with $7.5 million in 2014, escalating to $53.4 million in 2023, marking a sevenfold rise. This growth underscores their aggressive market strategies and increased administrative activities. Notably, Xencor's SG&A expenses consistently outpaced Alpine's, reflecting their larger market footprint. These trends offer valuable insights into each company's strategic priorities and operational growth over the years.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
argenx SE and Xencor, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Alpine Immune Sciences, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Alpine Immune Sciences, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Alpine Immune Sciences, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and ACADIA Pharmaceuticals Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Xencor, Inc.
Operational Costs Compared: SG&A Analysis of PTC Therapeutics, Inc. and Xencor, Inc.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.